Brent Dover doesn't join companies that have already made it. He joins the ones that are about to. His pattern - spotted across Medicity, Health Catalyst, Commure, Kalderos, and now Carta Healthcare - is consistent enough to be a system.
At Medicity, he was President from 2007 to 2012. When Aetna came calling in 2011, the check was $500 million and the return was 16x for investors. The company had built healthcare interoperability infrastructure at a time when most hospitals were still arguing about what "interoperability" meant.
He landed at Health Catalyst in 2013, taking the President role and owning everything client-facing - sales, implementation, support, the full arc of customer relationships. By 2018, when he stepped away, Health Catalyst was tracking toward its NASDAQ listing (ticker: HCAT). Two patterns in a row.
Commure was the third act. Dover took the CEO seat and built a FHIR-native open platform for healthcare developers. By 2021, the company's valuation had crossed $3.5 billion. The approach was different - developer infrastructure rather than direct healthcare delivery - but the outcome held the same shape: category leadership, significant valuation.
Then Kalderos: CEO role, drug discount transparency, the 340B space. A presentation at a STAT News virtual event on how technology could surface clarity in drug pricing - one of healthcare's most opaque corners.
"The team's unwavering passion for assisting healthcare professionals and harnessing the power of real-time clinical data left an indelible impression on me."- Brent Dover, on joining Carta Healthcare as CEO, December 2023
He joined Carta Healthcare in December 2023, succeeding co-founder Matt Hollingsworth. The pitch wasn't just the technology - it was the team's conviction about something most healthcare operators quietly know: clinical data is collected, and then it mostly sits there, incomplete and inaccessible.
Carta Healthcare's answer to this problem is what they call "Hybrid Intelligence." The company pairs AI-powered abstraction tools with over 200 expert human abstractors who have clinical backgrounds. It is not an either/or argument - it is a deliberate design choice. The machines handle volume and pattern recognition; the humans handle judgment, exception handling, and the kind of context that resists codification.
The results show it working. Health systems using the platform report cost reductions of 50% or more on their abstraction operations. Abstraction time drops by up to 66%. Accuracy lands at 98-99%.